Search Results - tlr

2 Results

Sort By:

Personalized Tumor Vaccine and Use Thereof for Cancer Immunotherapy

Abstract: Immune checkpoint inhibitors (ICIs) vastly improved the outcome of various advanced cancers; however, many are less likely to respond to single-agent ICI. Tumors with low T-cell infiltration are "immunologically cold" and less likely to respond to single-agent ICI therapy. This diminished response is presumably due to the lack of neoantigens...

Published: 4/8/2024 | Inventor(s): Zhengping (Ping) Zhuang, Karel Pacak, Jan Zenka, Rogelio Medina, Herui Wang, Sze Chun (Winson) Ho

Keywords(s): Anti-CD40-Monoclonal Antibody, CANCER, ICI, Immune Checkpoint Inhibitors, Mannan-BAM, Oncology, TLR, Toll-like receptor, Tumor Vaccine, Zhuang

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

Immunotherapy Combination Treatment Containing both TLR4 and TLR2/6 Agonists, a Checkpoint Inhibitor, and a STING agonist.

Abstract: Melanoma is an aggressive form of skin cancer that commonly becomes metastatic, spreading to nearby tissue or other parts of the body, including distant skin or subcutaneous sites such as the lungs, liver, brain, or bone. Metastatic melanoma is very drug resistant and difficult to treat, and therefore, the prognosis for these patients is poor....

Published: 5/22/2024 | Inventor(s): Md Alam, De Yang, Joost Oppenheim

Keywords(s): cGAMP, Combination Therapy, FSL-1, HMGN1, Immune Checkpoint Inhibitor, Immunotherapy, Melanin-Producing Melanoma, MELANOMA, Oppenheim, RESISTANT, STING Agonist, TLR, TLR2/6, TLR4, TLR4 Agonist, Toll-like receptor, TRL2/6 Agonist

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration